An observational study in Preterm Birth, sponsored by Hillel Yaffe Medical Center. Completed at 1 site in Israel. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2022-06-28.
Sponsored by Hillel Yaffe Medical Center · Observational
Heparanase is an endo-β-glucuronidase that cleaves heparin-sulfate (HS) side chains of heparan sulfate proteoglycans, an integral constituent of the extra cellular matrix (ECM).
This study aims to investigate the association between heparanase expression in the human placenta and preterm birth (PTB) .
The investigators hypothesize that an abnormal placentation causes relative placental ischemia that induces higher rates of heparanase expression.
2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.
This study's enrollment of 20 is below the median of 112 across 777 observational studies indexed under Premature Birth.
Browse Premature Birth studies →Hillel Yaffe Medical Center is the lead sponsor of 301 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Pregnant women attending our obstetrical unit
Exclusion Criteria:
Low-risk women undergoing elective term cesarean section
Other: Placental analysis
Low-risk women undergoing term vaginal delivery
Other: Placental analysis
Women undergoing preterm vaginal delivery
Other: Placental analysis
Analysis of placenta to determine expression of heparanase
Heparanase expression
Heparanase expression in the human placenta following delivery will be evaluated by western blot analysis in the three groups and will be compared to determine differences in the levels.
Time frame: Six months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hillel Yaffe Medical Center